Cambium Bio (ASX:CMB) Issuance of Debt: A$0.00 Mil (TTM As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.41
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Issuance of Debt?

Cambium Bio ASX:CMB 35 Issuance of Debt is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's Issuance of Debt for the six months ended in Dec. 2025 was A$0.00 Mil.

Cambium Bio's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Cambium Bio Issuance of Debt Related Terms

Cambium Bio Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Issuance of Debt Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.00 0.95 0.00 0.00

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of A$0.00 Mil mean?
Cambium Bio (ASX:CMB) has a Issuance of Debt of A$0.00 Mil as of Dec. 2025. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Cambium Bio and its competitors.
Is Cambium Bio's Issuance of Debt too high?
Cambium Bio's current Issuance of Debt is A$0.00 Mil. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Issuance of Debt compare to VRTX and REGN?
Cambium Bio's Issuance of Debt of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Cambium Bio and its competitors. Cambium Bio's current Issuance of Debt is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Issuance of Debt of A$0.00 Mil. The current Issuance of Debt is A$0.00 Mil. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Issuance of Debt is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price